These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1863728)

  • 21. [Prophylaxis with dantrolene sodium in 2 patients with susceptibility to malignant hyperthermia].
    Navas E; Sánchez-Peña J; Gutiérrez-Crespo A
    Rev Esp Anestesiol Reanim; 1992; 39(5):309-11. PubMed ID: 1410753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed Development of Malignant Hyperthermia Following Cardiopulmonary Bypass.
    Sams SH; Revilla S; Stahl DL
    Semin Cardiothorac Vasc Anesth; 2018 Mar; 22(1):95-99. PubMed ID: 28922985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass.
    Overand PT; Teply JF
    Anesth Analg; 1998 Jun; 86(6):1207-9. PubMed ID: 9620504
    [No Abstract]   [Full Text] [Related]  

  • 24. Controversies regarding the prophylactic use of dantrolene for malignant hyperthermia.
    Wingard DW
    Anesthesiology; 1983 May; 58(5):489-90. PubMed ID: 6838012
    [No Abstract]   [Full Text] [Related]  

  • 25. Malignant hyperthermia. Dantrolene--dynamics and kinetics.
    Harrison GG
    Br J Anaesth; 1988 Feb; 60(3):279-86. PubMed ID: 3279988
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects and arterial concentration of prostaglandin E1 during cardiopulmonary bypass.
    Okuda M; Faruhashi K; Konishi K; Muneyuki M
    Eur J Anaesthesiol; 1991 Mar; 8(2):129-34. PubMed ID: 1874208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bolus dose of 1.5 mg/kg amrinone effectively improves low cardiac output state following separation from cardiopulmonary bypass in cardiac surgical patients.
    Kikura M; Levy JH; Bailey JM; Shanewise JS; Michelsen LG; Sadel SM
    Acta Anaesthesiol Scand; 1998 Aug; 42(7):825-33. PubMed ID: 9698960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic use of dantrolene in a patient with central core disease.
    Michalek-Sauberer A; Gilly H
    Anesth Analg; 1998 Apr; 86(4):915-6. PubMed ID: 9539627
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiorespiratory effects of protamine after cardiopulmonary bypass in man.
    Jastrzebski J; Sykes MK; Woods DG
    Thorax; 1974 Sep; 29(5):534-8. PubMed ID: 4428453
    [No Abstract]   [Full Text] [Related]  

  • 30. Can we prevent malignant hyperthermia after hypothermic cardiopulmonary bypass in a malignant hyperthermia-susceptible patient?
    Siddik-Sayyid SM; Moussa AR; Baraka AS
    Anesth Analg; 2007 Jan; 104(1):214; author reply 214-5. PubMed ID: 17179280
    [No Abstract]   [Full Text] [Related]  

  • 31. Malignant hyperthermia in myelomeningocele: a previously unreported association.
    Anderson TE; Drummond DS; Breed AL; Taylor CA
    J Pediatr Orthop; 1981; 1(4):401-3. PubMed ID: 7334119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dantrolene in porcine malignant hyperthermia.
    Gronert GA; Milde JH; Theye RA
    Anesthesiology; 1976 Jun; 44(6):488-95. PubMed ID: 1275316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-anaesthetic administration of dantrolene sodium to a patient at risk from malignant hyperthermia: case report.
    Free CW; Jaimon MP
    N Z Med J; 1978 Dec; 88(626):493-4. PubMed ID: 283330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avoidance of malignant hyperthermia in a porcine model for experimental open heart surgery.
    Ehler WJ; Mack JW; Brown DL; Davis RF
    Lab Anim Sci; 1985 Apr; 35(2):172-5. PubMed ID: 3999703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Transient normalisation of CK blood levels in patients susceptible to malignant hyperthermia by oral administration of dantrolene (author's transl)].
    Bernhardt D
    Anaesthesist; 1982 May; 31(5):252-4. PubMed ID: 7103034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia.
    Watson CB; Reierson N; Norfleet EA
    Anesthesiology; 1986 Sep; 65(3):312-4. PubMed ID: 3752576
    [No Abstract]   [Full Text] [Related]  

  • 37. The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine.
    Harrison GG
    Br J Anaesth; 1977 Apr; 49(4):315-7. PubMed ID: 889645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant Hyperthermia: Review of Diagnosis and Treatment during Cardiac Surgery with Cardiopulmonary Bypass.
    Butala B; Busada M; Cormican D
    J Cardiothorac Vasc Anesth; 2018 Dec; 32(6):2771-2779. PubMed ID: 29730239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Postoperative respiratory depression thought to be due to oral dantrolene pretreatment in a malignant hyperthermia-susceptible patient].
    Hara Y; Kato A; Horikawa H; Kato Y; Ichiyanagi K
    Masui; 1988 Apr; 37(4):483-7. PubMed ID: 3398231
    [No Abstract]   [Full Text] [Related]  

  • 40. Malignant hyperthermia following preoperative oral administration of dantrolene.
    Fitzgibbons DC
    Anesthesiology; 1981 Jan; 54(1):73-5. PubMed ID: 7457985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.